Therefore, METs contribute to the promotion of pathological features in RA-FLSs through the cGAS/PI3K/Akt pathway, offering insights into potential therapeutic targets for treating RA (Figure 2) (31). This evidence concerns the gene CGAS and rheumatoid arthritis.